Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.

Abstract

Tumor necrosis factor (TNF) is a pro-inflammatory cytokine that plays a critical role in many inflammatory diseases. Soluble TNF can be neutralized by monoclonal antibodies (mAbs), and this is a widely-used therapeutic approach. However, some patients do not respond to anti-TNF therapy due to the increased expression of CD64 on monocytes and macrophages. A… (More)
DOI: 10.4161/mabs.32182

Topics

Cite this paper

@article{Hristodorov2014RecombinantHB, title={Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.}, author={Dmitrij Hristodorov and Radoslav Mladenov and Hannes Brehm and Rainer Fischer and Stefan Barth and Theo Thepen}, journal={mAbs}, year={2014}, volume={6 5}, pages={1283-9} }